[Heparin-induced thrombocytopenia].
Heparin treatment can cause an immune-mediated thrombocytopenia: HIT. HIT antibodies can be detected by various methods, but laboratory analyses are not specific or sensitive and may delay the diagnostic process. It is therefore important to initiate alternative treatment based on the clinical findings, and a clinical score system for evaluating the risk of HIT has been suggested. When HIT is likely, treatment consists of immediate replacement of heparin with alternative anticoagulation treatment and refrainment from warfarin therapy and platelet infusion.
Christoffersen
Christina
C
Klinisk Biokemisk Afdeling, Rigshospitalet, DK-2100 København Ø. christina.christoffersen@rh.regionh.dk
Lethagen
Stefan
S
Gøtze
Jens Peter
JP
D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D001120:Arginine / Q000031:analogs & derivatives; D002809:Chondroitin Sulfates / Q000627:therapeutic use; D003871:Dermatan Sulfate / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006493:Heparin / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000627:therapeutic use; D006629:Hirudins; D006801:Humans; D010875:Pipecolic Acids / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors; D013449:Sulfonamides; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy
D000925:Anticoagulants; D001120:Arginine; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D005343:Fibrinolytic Agents; D006493:Heparin; D006497:Heparan Sulfate; D006629:Hirudins; D010875:Pipecolic Acids; D011994:Recombinant Proteins; D013449:Sulfonamides; C035838:danaparoid; C031942:argatroban; C083544:lepirudin